Peter Gannon’s Post

Inefficient. Time-consuming. Frustrating. Often, these are the words used to describe the feasibility and site selection process for clinical trials. But, in this Clinical Leader Live, we will hear from experts from Johnson & Johnson Innovative Medicine, Takeda, and CSL Behring on ways they’ve been able to improve the feasibility assessment process. Reserve your spot for the May 30th event: https://lnkd.in/eP7T-r3E Speakers Mireille Ermens, Senior Director, Clinical Development Operations, Global Feasibility and Start Up Support, CSL Behring Monica Jain, Director, R&D Data Science, Johnson & Johnson Innovative Medicine Nick (Domenico) Palumbo, Director, Feasibility and Study Start-up, Takeda Dan Schell, Chief Editor, Clinical Leader #clinicaltrials #feasibility #digitalevent

Looking forward to be part of the presenters for this timely workshop: how to measure the impact of medical affairs activities?

When it comes to AI and medical affairs' evolving role in the life sciences, the real winners will be the early adopters of this technology and practices who are agile enough to make changes as new information becomes available. To get an early leg-up on your AI adoption, make sure to attend our upcoming webinar on June 25. The Envision and panel experts will go beyond the theoretical, offering a concrete vision of how AI can redefine every facet of medical work, creating a more efficient and effective pharmaceutical environment! https://lnkd.in/dKjvQS2K

❓ How can we create a truly patient-centered healthcare ecosystem? https://bit.ly/3YOqI3Q   Join our expert panel as they explore innovative strategies to enhance collaboration with healthcare professionals (HCPs) and better support patients. Key topics include:   • Integrating patient-centric initiatives into daily medical affairs to build trust with doctors and patients. • Providing continuous medical education (CME) to keep HCPs updated on the latest patient-focused solutions. • Building sustainable partnerships with hospitals to improve health literacy through clear, patient-friendly information.   Panelists: • Rohita Sharma, Senior Director, Global Patient Insights & Solutions, Alexion Pharmaceuticals, Inc. • Fiona Herr, VP, Global Head Immunology, Kyowa Kirin, Inc.- U.S. • Dr. Monique Gary, Chief Medical Officer, Bexa • Elizabeth Schumacher, CEO and Founder, Affinity Strategies   This panel is part of Pharma & Patient USA, the co-created event for patient champions in pharma who won’t sit back. This October, engage with leading pharma executives and patient advocates to learn first-hand how to drive change and build a brighter, more inclusive future in healthcare.   Are you ready to be the new beacon of trust? Join us to be in the room, be visible, and be engaged. Don’t miss out—limited tickets left! 💡🤝 #REpatientUSA #HealthcareInnovation #PatientCentricity #MedicalAffairs  

Don't miss this panel discussion on data dynamics in #medicalaffairs!

🌟 Exciting Event Alert! 🌟 Join us for an insightful evening at The Foundry, Cambridge on May 21st for the next chapter in our DCTs Monthly Series: "Diversity-Driven Pharma: Exploring Innovation in Digital Trials." 🔹 Keynote Speaker: Adriano Garcez BSc, MSc, MBA from ZS Associates will kick off the event with his presentation on "Harnessing Clinical and Real-World Data for Regulatory and Commercial Success: A Tale of People, Processes, and Validated Systems." 🔹 Panel Discussion: Dive deep into the world of digital health innovation with our esteemed panelists: Nicolas Encina – A visionary leader from Ariadne Labs and Brigham and Women's Hospital. Tony McDermott – VP of Global Commercial Strategy at Click Therapeutics, Inc., exploring the integration of digital therapeutics. Rashmi Gurnani – A trailblazer in digital health strategies. 🔹 Moderator: Aditya Tallapragada, a notable figure in the realm of digital clinical trials, will guide our discussion from AKT Health Inc. 🚀 Don’t miss out on this opportunity to network with industry leaders and learn how digital trials are revolutionizing inclusivity and participation in pharmaceutical research. 👉 Secure your spot now! Space fills up quickly for these events and RSVP will close. https://lnkd.in/eptrBve8 #DigitalHealth #PharmaInnovation #DiversityInPharma #DigitalTrials #HealthTechEvent

Anticipating the future of the clinical trials industry in 2024 has sparked countless discussions 🌟 What truly excites me is witnessing tangible strides in innovation, particularly in patient-informed clinical trial design. Significant investments in software development are poised to redefine primary endpoints, offering biotech R&D the advantage of reduced sample sizes and a more comprehensive approach to addressing the holistic needs of patients undergoing treatment. 🤗 In a recent PharmaVoice feature on Crystal Ball predictions, Marc Buyse compellingly advocates for 2024 as the year of patient-driven trial design. Explore the insights from Marc and other industry thought leaders on the significant developments ahead: https://lnkd.in/egPc8e9j 💡 I invite you to delve into these perspectives and share your thoughts, predictions, or hopes for the future of clinical trials, increasingly shaped by patient preferences. Connect with me or drop your ideas in the comments! 🚀

New Research Report - Download Now! Discover what’s working - and what’s not - in delivering a successful congress. 88% of corporate pharma congress planners say they’re facing significant challenges, citing a lack of alignment within their organizations as a major issue. "Value is being lost in the complexities of delivery" Our latest research, led by Katie Streten, Hannah McGill, and Annabel McClaren, uncovers: - The challenges faced by congress planners in pharma - What’s needed to overcome these challenges - How to improve the execution of future congresses Download the report today: https://lnkd.in/eiwH_Qs4 #medicalcongress #connectedcongress #congressplanning

Two Decades of Dedication: Celebrating Clinical Trials, Diversity, and the Future of AI Reflecting on 20 years in clinical trials, I am filled with gratitude. This journey has been a testament to the power of collaboration, innovation, and the relentless pursuit of knowledge. I extend my deepest thanks to the companies that have been part of my story: Bristol Myers Squibb, Roche, Avant Santé and MSD LATAM. Your commitment to healthcare excellence has been a beacon of inspiration. To the countless individuals I’ve met along the way, your support and insights have been invaluable. Together, we’ve navigated the complexities of clinical research, always with the patient’s well-being at heart. My journey has been driven by a commitment to diversity and inclusion. Ensuring that our trials reflect the diversity of the patients we serve is not just a professional goal—it’s a moral imperative. It’s about creating equitable access to cutting-edge treatments and making a tangible difference in people’s lives. As we look to the future, I am energized by the potential of AI and other emerging technologies. With leadership and responsibility, I am ready to harness these tools to bring more studies to fruition, benefiting an even broader patient population. Here’s to the next 20 years—may they be filled with continued passion, more inclusive studies, and transformative breakthroughs that benefit patients worldwide. Thank you!!! Pio #ClinicalTrials #DiversityAndInclusion #AI #HealthcareInnovation #PatientCare #20years

Important article for early stage biotechs planning to move into the clinic: experience in the strategic and operational aspects of drug development is critical in addition to the disease state knowledge that KOLs and SABs bring. TL:DR - you need a CMO. #chiefmedicalofficer #biotech #neuroscience